Evidence check: FADS1 in the context of menopause

The provided context lacks specific information on FADS1 in menopause. FADS1 encodes delta-5 desaturase, a key enzyme in the conversion of alpha-linolenic acid (ALA) to long-chain omega-3 fatty acids (EPA/DHA). During menopause, declining estrogen alters lipid metabolism and inflammation. GWAS studies have linked FADS1 variants to differences in omega-3 levels, which could theoretically influence menopausal symptoms like hot flashes, bone health, or cardiovascular risk. However, effect sizes are modest, and no robust human trials directly demonstrate that acting on FADS1 results improves menopausal outcomes. Consumer DNA tests reporting FADS1 variants offer lifestyle inspiration, not clinical guidance. The evidence is best described as GWAS-based and mechanistic, not practice-ready. Any dietary changes (e.g., increasing omega-3 intake) should be discussed with a healthcare provider. The test's marketing may overstate the actionable value.